302 related articles for article (PubMed ID: 35457081)
1. Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy.
Matsumoto Y
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457081
[TBL] [Abstract][Full Text] [Related]
2. DNA-Dependent Protein Kinase Catalytic Subunit: The Sensor for DNA Double-Strand Breaks Structurally and Functionally Related to Ataxia Telangiectasia Mutated.
Matsumoto Y; Asa ADDC; Modak C; Shimada M
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440313
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
5. DNA-PK-dependent phosphorylation of Ku70/80 is not required for non-homologous end joining.
Douglas P; Gupta S; Morrice N; Meek K; Lees-Miller SP
DNA Repair (Amst); 2005 Aug; 4(9):1006-18. PubMed ID: 15941674
[TBL] [Abstract][Full Text] [Related]
6. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
7. The catalytic subunit of DNA-dependent protein kinase is required for cellular resistance to oxidative stress independent of DNA double-strand break repair.
Li M; Lin YF; Palchik GA; Matsunaga S; Wang D; Chen BP
Free Radic Biol Med; 2014 Nov; 76():278-85. PubMed ID: 25224041
[TBL] [Abstract][Full Text] [Related]
8. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.
Sun Q; Guo Y; Liu X; Czauderna F; Carr MI; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2019 Dec; 17(12):2457-2468. PubMed ID: 31551253
[TBL] [Abstract][Full Text] [Related]
10. Modeling the interplay between DNA-PK, Artemis, and ATM in non-homologous end-joining repair in G1 phase of the cell cycle.
Rouhani M
J Biol Phys; 2019 Jun; 45(2):127-146. PubMed ID: 30707386
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the role of distinct DNA-PK phosphorylations at collapsed replication forks.
Neal JA; Dunger K; Geith K; Meek K
DNA Repair (Amst); 2020 Oct; 94():102925. PubMed ID: 32674014
[TBL] [Abstract][Full Text] [Related]
12. DNA-PK and ATM phosphorylation sites in XLF/Cernunnos are not required for repair of DNA double strand breaks.
Yu Y; Mahaney BL; Yano K; Ye R; Fang S; Douglas P; Chen DJ; Lees-Miller SP
DNA Repair (Amst); 2008 Oct; 7(10):1680-92. PubMed ID: 18644470
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human polλ by ATM-mediated phosphorylation during non-homologous end joining.
Sastre-Moreno G; Pryor JM; Moreno-Oñate M; Herrero-Ruiz AM; Cortés-Ledesma F; Blanco L; Ramsden DA; Ruiz JF
DNA Repair (Amst); 2017 Mar; 51():31-45. PubMed ID: 28109743
[TBL] [Abstract][Full Text] [Related]
14. Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence.
Liu Y; Efimova EV; Ramamurthy A; Kron SJ
J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31189537
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair.
Kelm JM; Samarbakhsh A; Pillai A; VanderVere-Carozza PS; Aruri H; Pandey DS; Pawelczak KS; Turchi JJ; Gavande NS
Front Oncol; 2022; 12():850883. PubMed ID: 35463312
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
Yang SH; Kuo TC; Wu H; Guo JC; Hsu C; Hsu CH; Tien YW; Yeh KH; Cheng AL; Kuo SH
World J Gastroenterol; 2016 Aug; 22(32):7275-88. PubMed ID: 27621574
[TBL] [Abstract][Full Text] [Related]
17. Genetic interaction between DNA repair factors PAXX, XLF, XRCC4 and DNA-PKcs in human cells.
Xing M; Oksenych V
FEBS Open Bio; 2019 Jul; 9(7):1315-1326. PubMed ID: 31141305
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome dataset of HEK293T cells depleted of one of the subunits of the DNA-PK complex: Ku70, Ku80 or DNA-PKcs.
Anisenko A; Shadrina O; Garanina I; Gottikh M
Data Brief; 2021 Dec; 39():107596. PubMed ID: 34849385
[TBL] [Abstract][Full Text] [Related]
19. The fructose-bisphosphate, Aldolase A (ALDOA), facilitates DNA-PKcs and ATM kinase activity to regulate DNA double-strand break repair.
Sobanski T; Suraweera A; Burgess JT; Richard I; Cheong CM; Dave K; Rose M; Adams MN; O'Byrne KJ; Richard DJ; Bolderson E
Sci Rep; 2023 Sep; 13(1):15171. PubMed ID: 37704669
[TBL] [Abstract][Full Text] [Related]
20. Roles for the DNA-PK complex and 53BP1 in protecting ends from resection during DNA double-strand break repair.
Shibata A; Jeggo PA
J Radiat Res; 2020 Sep; 61(5):718-726. PubMed ID: 32779701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
